Literature DB >> 12163369

PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.

Xiao-Ping Zhou1, Anu Loukola, Reijo Salovaara, Minna Nystrom-Lahti, Päivi Peltomäki, Albert de la Chapelle, Lauri A Aaltonen, Charis Eng.   

Abstract

PTEN on 10q23.3 encodes a dual-specificity phosphatase that negatively regulates the phosphoinositol-3-kinase/Akt pathway and mediates cell-cycle arrest and apoptosis. Germline PTEN mutations cause Cowden syndrome and a range of several different hamartoma-tumor syndromes. Hereditary nonpolyposis colon cancer (HNPCC) syndrome is characterized by germline mutations in the mismatch repair (MMR) genes and by microsatellite instability (MSI) in component tumors. Although both colorectal carcinoma and endometrial carcinoma are the most frequent component cancers in HNPCC, only endometrial cancer has been shown to be a minor component of Cowden syndrome. We have demonstrated that somatic inactivation of PTEN is involved in both sporadic endometrial cancers and HNPCC-related endometrial cancers but with different mutational spectra and different relationships to MSI. In the current study, we sought to determine the relationship of PTEN mutation, 10q23 loss of heterozygosity, PTEN expression, and MSI status in colorectal cancers (CRCs). Among 11 HNPCC CRCs, 32 MSI+ sporadic cancers, and 39 MSI- tumors, loss of heterozygosity at 10q23.3 was found in 0%, 8%, and 19%, respectively. Somatic mutations were found in 18% (2 of 11) of the HNPCC CRCs and 13% (4 of 32) of the MSI+ sporadic tumors, but not in MSI- cancers (P = 0.015). All somatic mutations occurred in the two 6(A) coding mononucleotide tracts in PTEN, suggestive of the etiological role of the deficient MMR. Immunohistochemical analysis revealed 31% (14 of 45) of the HNPCC CRCs and 41% (9 of 22) of the MSI+ sporadic tumors with absent or depressed PTEN expression. Approximately 17% (4 of 23) of the MSI- CRCs had decreased PTEN expression, and no MSI- tumor had complete loss of PTEN expression. Among the five HNPCC or MSI+ sporadic CRCs carrying frameshift somatic mutations with immunohistochemistry data, three had lost all PTEN expression, one showed weak PTEN expression levels, and one had mixed tumor cell populations with weak and moderate expression levels. These results suggest that PTEN frameshift mutations in HNPCC and sporadic MSI+ tumors are a consequence of mismatch repair deficiency. Further, hemizygous deletions in MSI- CRCs lead to loss or reduction of PTEN protein levels and contribute to tumor progression. Finally, our data also suggest that epigenetic inactivation of PTEN, including differential subcellular compartmentalization, occurs in CRCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163369      PMCID: PMC1850747          DOI: 10.1016/S0002-9440(10)64200-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  Will the real Cowden syndrome please stand up: revised diagnostic criteria.

Authors:  C Eng
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

2.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells.

Authors:  D M Li; H Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death.

Authors:  L P Weng; O Gimm; J B Kum; W M Smith; X P Zhou; D Wynford-Thomas; G Leone; C Eng
Journal:  Hum Mol Genet       Date:  2001-02-01       Impact factor: 6.150

5.  PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways.

Authors:  L Weng; J Brown; C Eng
Journal:  Hum Mol Genet       Date:  2001-02-01       Impact factor: 6.150

6.  Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations.

Authors:  X P Zhou; Y J Li; K Hoang-Xuan; P Laurent-Puig; K Mokhtari; M Longy; M Sanson; J Y Delattre; G Thomas; R Hamelin
Journal:  Int J Cancer       Date:  1999-04-20       Impact factor: 7.396

7.  PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma.

Authors:  H B Salvesen; N MacDonald; A Ryan; I J Jacobs; E D Lynch; L A Akslen; S Das
Journal:  Int J Cancer       Date:  2001-01-01       Impact factor: 7.396

8.  PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.

Authors:  D J Marsh; J B Kum; K L Lunetta; M J Bennett; R J Gorlin; S F Ahmed; J Bodurtha; C Crowe; M A Curtis; M Dasouki; T Dunn; H Feit; M T Geraghty; J M Graham; S V Hodgson; A Hunter; B R Korf; D Manchester; S Miesfeldt; V A Murday; K L Nathanson; M Parisi; B Pober; C Romano; C Eng
Journal:  Hum Mol Genet       Date:  1999-08       Impact factor: 6.150

9.  Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers.

Authors:  A Duval; S Rolland; A Compoint; E Tubacher; B Iacopetta; G Thomas; R Hamelin
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

10.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

View more
  78 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  Intestinal epithelial-specific PTEN inactivation results in tumor formation.

Authors:  Do-Sun Byun; Naseem Ahmed; Shannon Nasser; Joongho Shin; Sheren Al-Obaidi; Sanjay Goel; Georgia A Corner; Andrew J Wilson; Dustin J Flanagan; David S Williams; Leonard H Augenlicht; Elizabeth Vincan; John M Mariadason
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

3.  Association of genetic polymorphisms in PTEN and additional interaction with alcohol consumption and smoking on colorectal cancer in Chinese population.

Authors:  Mingyang Han; Gang Wu; Peichun Sun; Jiewei Nie; Jiancheng Zhang; Yuanyuan Li
Journal:  Int J Clin Exp Med       Date:  2015-11-15

4.  Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray.

Authors:  Wei-Chang Chen; Mao-Song Lin; Bao-Feng Zhang; Jing Fang; Qiong Zhou; Ying Hu; Heng-Jun Gao
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

5.  Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.

Authors:  Farhan Khan; Ashwini Esnakula; Luisel J Ricks-Santi; Rabia Zafar; Yasmine Kanaan; Tammey Naab
Journal:  Pathol Res Pract       Date:  2018-03-27       Impact factor: 3.250

6.  No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer.

Authors:  Lynette S Phillips; Cheryl L Thompson; Alona Merkulova; Sarah J Plummer; Thomas C Tucker; Graham Casey; Li Li
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

7.  KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.

Authors:  Guoliang Li; Thanigaivelan Kanagasabai; Wenfu Lu; Mike R Zou; Shang-Min Zhang; Sherly I Celada; Michael G Izban; Qi Liu; Tao Lu; Billy R Ballard; Xinchun Zhou; Samuel E Adunyah; Robert J Matusik; Qin Yan; Zhenbang Chen
Journal:  Cancer Res       Date:  2020-08-31       Impact factor: 12.701

8.  Expression of PPARγ and PTEN in human colorectal cancer: An immunohistochemical study using tissue microarray methodology.

Authors:  Mao Song Lin; Jun Xing Huang; Wei Chang Chen; Bao Feng Zhang; Jing Fang; Qiong Zhou; Ying Hu; Heng Jun Gao
Journal:  Oncol Lett       Date:  2011-09-06       Impact factor: 2.967

9.  PTEN inhibits BMI1 function independently of its phosphatase activity.

Authors:  Catherine Fan; Lizhi He; Anil Kapoor; Adrian P Rybak; Jason De Melo; Jean-Claude Cutz; Damu Tang
Journal:  Mol Cancer       Date:  2009-11-10       Impact factor: 27.401

10.  Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function.

Authors:  Glenn P Lobo; Kristin A Waite; Sarah M Planchon; Todd Romigh; Najah T Nassif; Charis Eng
Journal:  Hum Mol Genet       Date:  2009-05-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.